NASDAQ:ALDX
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. reported net income of −$33.8M in fiscal 2025. The diluted share count rose 1.0%.Summary generated from Aldeyra Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−261.8%
Return on equity−58.7%
Debt / equity0.35
Free cash flown/a
FCF marginn/a
Share count change+1.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −56 | −63 | −43 | −60 | −35 |
| Net income | −58 | −62 | −38 | −56 | −34 |
| Free cash flow | −43 | −57 | −30 | n/a | n/a |
Recent filings
- 8-KRegulation FD disclosure
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KEntry into a material agreement
Jul 30, 2026 - 8-KOther events
Jul 15, 2026 - 4Insider transaction report
Jun 11, 2026 - 4Insider transaction report
Jun 11, 2026 - 8-KDirector or officer change
Jun 10, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026